An open-label clinical trial reported durable remission in a refractory lupus nephritis patient after allogeneic CD19-directed CAR-NK cell therapy. The case reinforces interest in off-the-shelf immune effector strategies for autoimmunity, particularly for patients who progress despite standard immunosuppression. While single-patient data cannot establish breadth, the durability signal suggests a potentially meaningful therapeutic window for CAR-NK platforms in organ-threatening autoimmune disease.